Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candonilimab Plus Bevacizumab in Advanced Hepatocellular Carcinoma
NCT05760599Phase 2Unknown
- Sponsor
- Shiming Biotech
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Shiming Biotech. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05760599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760599.